Intravenous Iron in Patients Undergoing Maintenance Hemodialysis: the PIVOTAL trial

Feb 14, 2019

Overview : Trial References Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, and Ford I, for the PIVOTAL Investigators and Committees. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.... more

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

Nov 14, 2018

Overview : Trial Reference Velazquez EJ, Morrow DA, DeVore AD, et al., for the PIONEER-HF Investigators. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2018 Nov 11 [epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas. Professor of Medicine, Universidad de... more

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (MARINER)

Sep 13, 2018

Overview : Trial References Spyropoulos AC, Ageno W, Albers GW, et al.; MARINER Investigators. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1805090. Abstract | Full Text Expert Comment Pablo del Castillo Vazquez,  Antoni Martínez-Rubio: Department of Cardiology, University Hospital of... more

Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients (CAMELLIA–TIMI 61)

Sep 13, 2018

Overview : Trial References Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients - Thrombolysis in Myocardial Infarction 61 (CAMELLIA–TIMI 61) Expert Comment Amelia Carro. Hospital Universitario Vall d’Hebrón. Universidad Autónoma de Barcelona, Barcelona, Spain. Background Obesity is a major... more

Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE Trial)

Aug 27, 2018

Overview : Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomised, Double-blind, Placebo-controlled Trial Trial Reference Gaziano JM, Brotons C, Coppolecchia R, et al. Use of Aspirin to Reduce Risk... more

A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest

Aug 27, 2018

Overview : Trial Reference Perkins GD, Ji C, Deakin CD, et al.; PARAMEDIC2 Collaborators. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2018 Jul 18. doi: 10.1056/NEJMoa1806842. [Epub ahead of print] Abstract | Full Text Expert Comment Pablo Avanzas, Consultant... more

Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

May 22, 2018

Overview : Trial Reference Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM. Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes.  J Am Coll Cardiol. 2018 Mar 3. pii: S0735-1097(18)33483-1. doi: 10.1016/j.jacc.2018.03.002.... more

Effect of Loading Dose of Atorvastatin Prior to Planned PCI: The SECURE-PCI Randomized Clinical Trial

Apr 18, 2018

Overview : Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome. The SECURE-PCI Randomized Clinical Trial   Trial References Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin... more

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

Mar 22, 2018

Overview : Trial Reference White WB, Saag KG, Becker MA, et al; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 12. doi: 10.1056/NEJMoa1710895. [Epub ahead of print] Abstract | Full Text   Expert Comment... more

6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial

Mar 20, 2018

Overview : Trial Reference Hahn JY, Song YB, Oh JH, et al; SMART-DATE investigators. 6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial. Lancet. 2018 Mar 9.... more

Page: